Diabetes, Vol 46, Issue 2 317-322, Copyright © 1997 by American Diabetes Association

ARTICLES

Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression

GS Korbutt, JF Elliott and RV Rajotte
Surgical-Medical Research Institute, University of Alberta, Edmonton, Canada.

We prepared single-cell suspensions of Lewis rat ?RT1(1/l)? testicular cells and cultured these in vitro for 48 h under conditions that promoted the formation of cellular aggregates. In the absence of systemic immunosuppression, the transplantation of a sufficient quantity of these aggregates (containing 11 x 10(6) cells, (75% Sertoli cells), together with 2,000 purified Lewis rat islets, reversed the diabetic state for >95 days in 100% (5/5) of the chemically diabetic Wistar-Furth ?RT1(u/u)? recipients. Similar grafts consisting of islets alone or islets plus 50% fewer testicular cell aggregates survived for only 10 days. Functioning composite allografts harvested from normoglycemic animals at approximately 100 days showed healthy beta-cells in close association with Fas ligand-expressing Sertoli cells. Because no gene therapy protocol is required, the transplantation of composite grafts consisting of purified human allogeneic islets plus human allogeneic testicular cell aggregates can be applied in clinical islet transplantation as soon as it has been proven in a large animal model.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. Sipione, K. C. Simmen, S. J. Lord, B. Motyka, C. Ewen, I. Shostak, G. R. Rayat, J. M. Dufour, G. S. Korbutt, R. V. Rajotte, et al. Identification of a Novel Human Granzyme B Inhibitor Secreted by Cultured Sertoli Cells J. Immunol., October 15, 2006; 177(8): 5051 - 5058. [Abstract] [Full Text] [PDF]

				W. -L. Kuan and R. A. Barker New Therapeutic Approaches to Parkinson's Disease Including Neural Transplants Neurorehabil Neural Repair, September 1, 2005; 19(3): 155 - 181. [Abstract] [PDF]

				M. K. O'Bryan, O. Gerdprasert, D. J. Nikolic-Paterson, A. Meinhardt, J. A. Muir, L. M. Foulds, D. J. Phillips, D. M. de Kretser, and M. P. Hedger Cytokine profiles in the testes of rats treated with lipopolysaccharide reveal localized suppression of inflammatory responses Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2005; 288(6): R1744 - R1755. [Abstract] [Full Text] [PDF]

				N. Sofikitis, E. Pappas, A. Kawatani, D. Baltogiannis, D. Loutradis, N. Kanakas, D. Giannakis, F. Dimitriadis, K. Tsoukanelis, I. Georgiou, et al. Efforts to create an artificial testis: culture systems of male germ cells under biochemical conditions resembling the seminiferous tubular biochemical environment Hum. Reprod. Update, May 1, 2005; 11(3): 229 - 259. [Abstract] [Full Text] [PDF]

				J. M. Dufour, M. Hamilton, R. V. Rajotte, and G. S. Korbutt Neonatal Porcine Sertoli Cells Inhibit Human Natural Antibody-Mediated Lysis Biol Reprod, May 1, 2005; 72(5): 1224 - 1231. [Abstract] [Full Text] [PDF]

				O. Bohana-Kashtan and C. I. Civin Fas Ligand as a Tool for Immunosuppression and Generation of Immune Tolerance Stem Cells, November 1, 2004; 22(6): 908 - 924. [Abstract] [Full Text] [PDF]

				J. M. Dufour, R. V. Rajotte, and G. S. Korbutt Development of an In Vivo Model to Study Testicular Morphogenesis J Androl, September 1, 2002; 23(5): 635 - 644. [Abstract] [Full Text] [PDF]

				L. Tourneur, B. Malassagne, F. Batteux, M. Fabre, S. Mistou, E. Lallemand, P. Lores, and G. Chiocchia Transgenic Expression of CD95 Ligand on Thyroid Follicular Cells Confers Immune Privilege upon Thyroid Allografts J. Immunol., August 1, 2001; 167(3): 1338 - 1346. [Abstract] [Full Text] [PDF]

				W.-P. Min, R. Gorczynski, X.-Y. Huang, M. Kushida, P. Kim, M. Obataki, J. Lei, R. M. Suri, and M. S. Cattral Dendritic Cells Genetically Engineered to Express Fas Ligand Induce Donor-Specific Hyporesponsiveness and Prolong Allograft Survival J. Immunol., January 1, 2000; 164(1): 161 - 167. [Abstract] [Full Text] [PDF]

				J. O'Connell, M. W. Bennett, G. C. O'Sullivan, J. O'Callaghan, J. K. Collins, and F. Shanahan Expression of Fas (CD95/APO-1) Ligand by Human Breast Cancers: Significance for Tumor Immune Privilege Clin. Vaccine Immunol., July 1, 1999; 6(4): 457 - 463. [Abstract] [Full Text] [PDF]

				R. Arnold, M. Seifert, K. Asadullah, and H. D. Volk Crosstalk Between Keratinocytes and T Lymphocytes via Fas/Fas Ligand Interaction: Modulation by Cytokines J. Immunol., June 15, 1999; 162(12): 7140 - 7147. [Abstract] [Full Text] [PDF]

				R. F. McClure, C. J. Heppelmann, and C. V. Paya Constitutive Fas Ligand Gene Transcription in Sertoli Cells Is Regulated By Sp1 J. Biol. Chem., March 19, 1999; 274(12): 7756 - 7762. [Abstract] [Full Text] [PDF]

				M W Bennett, J O'Connell, G C O'Sullivan, D Roche, C Brady, J Kelly, J K Collins, and F Shanahan Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer Gut, February 1, 1999; 44(2): 156 - 162. [Abstract] [Full Text] [PDF]

				M. W. Bennett, J. O'Connell, G. C. O'Sullivan, C. Brady, D. Roche, J. K. Collins, and F. Shanahan The Fas Counterattack In Vivo: Apoptotic Depletion of Tumor-Infiltrating Lymphocytes Associated with Fas Ligand Expression by Human Esophageal Carcinoma J. Immunol., June 1, 1998; 160(11): 5669 - 5675. [Abstract] [Full Text] [PDF]